You can read the newsletter by Northside Hospital if you CLICK HERE. Two very interesting graphs compare Northside’s data against other programs in its region of the country and against the best known national programs. The graphs are noted below:
You can find data for all of the Allogeneic programs that report data to the National Marrow Donor Program (NMDP) if you CLICK HERE. It will show a listing by state, and you just click on the name and review all of their data by disease type.
Now, what is the take away from these findings. First, if you are a cancer patient who can benefit from an allo (mainly leukemia and lymphoma) the data is there for you to choose a location that is at least 2 times more likely to keep you alive for the first year. All of the locations listed on the NMDP site has this data and should be able to tell you, and if they do not you can now find it yourself. Unfortunately, these same locations also have similar data for survival for the auto transplant, but have as yet chosen not to make this public. However they do have access to this information and should be able to provide it to you. If they do not give it to you, they are either unaware of its existence, or just are afraid to provide their below average performance to their patients. What should be happening is locations that are not performing to the highest standard for allos should be finding out what the Northside Hospitals of the world are doing that make them the best of the best and duplicate it in their practice.
I think what the NMDP is doing for the allo is a game changer, and very brave of all the membership hospitals that has chosen to participate, however it should be expanded to include the auto transplant, and ultimately for all cancers. This is the vision that Dr. Hofmeister has for myeloma and would be expandable to all cancers with the Ohio Myeloma Initiative. You can read about this if you CLICK HERE. Consumer Reports is also looking to provide survival performance by center for all cancers, and this is a potential game changer as well.
The fact that I continue to see progress in the area of survival outcome based performance by facility bodes well for future improvements in cancer life expectancy. Like a very insightful mentor of mine once stated: “You can not improve that which you do not measure”. This is no different for cancer treatment, and finally it looks like we are moving in that direction.
Good luck and may God Bless your Cancer Journey. For more information onmultiple myeloma survival rates and treatments CLICK HERE and you can follow me on twitter at: https://twitter.com/grpetersen1